Celcuity Inc. - SIC # 8081 -

Ticker Exchange SIC # Website Latest Ticker
CELC Nasdaq 8081 www.celcuity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celcuity Inc.

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call - Aug 6th, 2026 6:34 am
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer - Jul 30th, 2026 6:30 am
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits - Jul 15th, 2026 2:16 pm
Celcuity gains FDA approval for closely watched breast cancer drug - Jul 15th, 2026 6:18 am
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer - Jul 15th, 2026 2:02 am
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Jul 14th, 2026 3:24 pm
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer - Jul 14th, 2026 2:53 pm
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now - Jun 19th, 2026 6:24 am
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering - Jun 4th, 2026 1:11 pm
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients - Jun 4th, 2026 3:07 am
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032 - Jun 3rd, 2026 8:13 pm
US Equity Futures Mixed Pre-Bell as US, Iran Continue Military Strikes in Middle East - Jun 3rd, 2026 7:04 am
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 - Jun 3rd, 2026 5:19 am
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Jun 2nd, 2026 2:56 pm
Celcuity Crashes On Breast Cancer Disappointment. What Happened? - Jun 2nd, 2026 2:28 pm
Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial - Jun 2nd, 2026 1:09 pm
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial - Jun 2nd, 2026 9:52 am
Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC) - Jun 2nd, 2026 7:40 am
Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer - Jun 2nd, 2026 6:25 am
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026 - Jun 1st, 2026 6:30 am